Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 377

1.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

Obstet Gynecol. 2018 Aug;132(2):261-270. doi: 10.1097/AOG.0000000000002736.

PMID:
29995724
2.

Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases.

Alejo M, Alemany L, Clavero O, Quiros B, Vighi S, Seoud M, Cheng-Yang C, Garland SM, Juanpere N, Lloreta J, Tous S, Klaustermeier JE, Quint W, Bosch FX, de Sanjosé S, Lloveras B; RIS HPV TT study group.

Papillomavirus Res. 2018 Jun;5:134-142. doi: 10.1016/j.pvr.2018.03.005. Epub 2018 Mar 17.

3.

Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients.

Mena M, Taberna M, Tous S, Marquez S, Clavero O, Quiros B, Lloveras B, Alejo M, Leon X, Quer M, Bagué S, Mesia R, Nogués J, Gomà M, Aguila A, Bonfill T, Blazquez C, Guix M, Hijano R, Torres M, Holzinger D, Pawlita M, Pavon MA, Bravo IG, de Sanjosé S, Bosch FX, Alemany L.

Oral Oncol. 2018 Mar;78:137-144. doi: 10.1016/j.oraloncology.2018.01.010. Epub 2018 Feb 20.

PMID:
29496041
4.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

5.

HPV distribution in cervical cancer in Portugal. A retrospective study from 1928 to 2005.

Félix A, Alemany L, Tous S, de Sanjosé S, Bosch FX.

Papillomavirus Res. 2016 Dec;2:41-45. doi: 10.1016/j.pvr.2016.02.003. Epub 2016 Mar 2.

6.

Epidemiology and burden of HPV-related disease.

Serrano B, Brotons M, Bosch FX, Bruni L.

Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:14-26. doi: 10.1016/j.bpobgyn.2017.08.006. Epub 2017 Sep 2. Review.

PMID:
29037457
7.

Effect of age-difference between heterosexual partners on risk of cervical cancer and human papillomavirus infection.

Baussano I, Diaz M, Tully S, Muñoz N, de Sanjosé S, Bosch FX, Franceschi S.

Papillomavirus Res. 2017 Jun;3:98-104. doi: 10.1016/j.pvr.2017.03.003. Epub 2017 Mar 19.

8.

Squamous intraepithelial lesions of the anal squamocolumnar junction: Histopathological classification and HPV genotyping.

Clavero O, McCloskey J, Molina VM, Quirós B, Bravo IG, de Sanjosé S, Bosch FX, Pimenoff VN.

Papillomavirus Res. 2017 Jun;3:11-17. doi: 10.1016/j.pvr.2016.12.001. Epub 2016 Dec 9.

9.

[Human papillomavirus nonavalent vaccine. Update 2017].

Bosch FX, Moreno D, Redondo E, Torné A.

Semergen. 2017 May - Jun;43(4):265-276. doi: 10.1016/j.semerg.2017.04.010. Epub 2017 May 23. Spanish.

PMID:
28549940
10.

Human papillomavirus 16 is an aetiological factor of scrotal cancer.

Guimerà N, Alemany L, Halec G, Pawlita M, Wain GV, Vailén JSS, Azike JE, Jenkins D, de Sanjosé S, Quint W, Bosch FX.

Br J Cancer. 2017 Apr 25;116(9):1218-1222. doi: 10.1038/bjc.2017.74. Epub 2017 Apr 4.

11.

Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma.

Holzinger D, Wichmann G, Baboci L, Michel A, Höfler D, Wiesenfarth M, Schroeder L, Boscolo-Rizzo P, Herold-Mende C, Dyckhoff G, Boehm A, Del Mistro A, Bosch FX, Dietz A, Pawlita M, Waterboer T.

Int J Cancer. 2017 Jun 15;140(12):2748-2757. doi: 10.1002/ijc.30697. Epub 2017 Apr 4.

12.

Medullary Carcinoma of the Penis: A Distinctive HPV-related Neoplasm: A Report of 12 Cases.

Cañete-Portillo S, Clavero O, Sanchez DF, Silvero A, Abed F, Rodriguez IM, Ayala G, Alemany L, Munoz N, de Sanjose S, Quint W, Bosch FX, Cubilla AL.

Am J Surg Pathol. 2017 Apr;41(4):535-540. doi: 10.1097/PAS.0000000000000779.

PMID:
28291123
13.

Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.

Nicolás-Párraga S, Alemany L, de Sanjosé S, Bosch FX, Bravo IG; RIS HPV TT and HPV VVAP study groups.

Int J Cancer. 2017 May 1;140(9):2092-2100. doi: 10.1002/ijc.30636. Epub 2017 Mar 1.

14.

Biological relevance of human papillomaviruses in vulvar cancer.

Halec G, Alemany L, Quiros B, Clavero O, Höfler D, Alejo M, Quint W, Pawlita M, Bosch FX, de Sanjose S.

Mod Pathol. 2017 Apr;30(4):549-562. doi: 10.1038/modpathol.2016.197. Epub 2017 Jan 6.

15.

HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.

Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C, Lazcano-Ponce E.

Salud Publica Mex. 2016 Apr;58(2):211-9.

16.

Eradication of cervical cancer in Latin America.

Bosch FX.

Salud Publica Mex. 2016 Apr;58(2):97-100. No abstract available.

17.

Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.

Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Limson G, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Del Rosario-Raymundo MR, Catteau G, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Int J Cancer. 2016 Dec 15;139(12):2812-2826. doi: 10.1002/ijc.30391. Epub 2016 Sep 9.

18.

Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan.

Loya A, Serrano B, Rasheed F, Tous S, Hassan M, Clavero O, Raza M, De Sanjosé S, Bosch FX, Alemany L.

Cancers (Basel). 2016 Jul 30;8(8). pii: E72. doi: 10.3390/cancers8080072.

19.

Corrigendum to "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines" [Vaccine 34 (2016) 757-761].

Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJLM, Petry KU, Soubeyrand B, Verstraeten T, Stanley M.

Vaccine. 2016 Sep 7;34(39):4759-4760. doi: 10.1016/j.vaccine.2016.07.035. Epub 2016 Jul 25. No abstract available.

20.

Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.

Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A.

Pediatrics. 2016 Aug;138(2). pii: e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15.

21.

Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.

Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X.

Lancet Glob Health. 2016 Jul;4(7):e453-63. doi: 10.1016/S2214-109X(16)30099-7. Erratum in: Lancet Glob Health. 2017 Jul;5(7):e662.

22.

Correction: The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.

Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, Pala V, Weiderpass E, Margall N, Dillner J, Gram IT, Tjønneland A, Munk C, Palli D, Khaw KT, Overvad K, Clavel-Chapelon F, Mesrine S, Fournier A, Fortner RT, Ose J, Steffen A, Trichopoulou A, Lagiou P, Orfanos P, Masala G, Tumino R, Sacerdote C, Polidoro S, Mattiello A, Lund E, Peeters PH, Bueno-de-Mesquita HB, Ramón Quirós J, Sánchez MJ, Navarro C, Barricarte A, Larrañaga N, Ekström J, Lindquist D, Idahl A, Travis RC, Merritt MA, Gunter MJ, Rinaldi S, Tommasino M, Franceschi S, Riboli E, Castellsagué X.

PLoS One. 2016 Mar 8;11(3):e0151427. doi: 10.1371/journal.pone.0151427. eCollection 2016. No abstract available.

23.

The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.

Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, Pala V, Weiderpass E, Margall N, Dillner J, Gram IT, Tjønneland A, Munk C, Palli D, Khaw KT, Overvad K, Clavel-Chapelon F, Mesrine S, Fournier A, Fortner RT, Ose J, Steffen A, Trichopoulou A, Lagiou P, Orfanos P, Masala G, Tumino R, Sacerdote C, Polidoro S, Mattiello A, Lund E, Peeters PH, Bueno-de-Mesquita HB, Quirós JR, Sánchez MJ, Navarro C, Barricarte A, Larrañaga N, Ekström J, Lindquist D, Idahl A, Travis RC, Merritt MA, Gunter MJ, Rinaldi S, Tommasino M, Franceschi S, Riboli E, Castellsagué X.

PLoS One. 2016 Jan 25;11(1):e0147029. doi: 10.1371/journal.pone.0147029. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0151427.

24.

Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.

Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M.

Vaccine. 2016 Feb 3;34(6):757-61. doi: 10.1016/j.vaccine.2015.12.063. Epub 2016 Jan 6. Erratum in: Vaccine. 2016 Sep 7;34(39):4759-4760.

25.

Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia 1950-1999.

Sanchez GI, Bravo LE, Hernandez-Suarez G, Tous S, Alemany L, de Sanjose S, Bosch FX, Muñoz N.

Cancer Epidemiol. 2016 Feb;40:173-8. doi: 10.1016/j.canep.2015.12.008. Epub 2016 Jan 6.

PMID:
26771314
26.

Role of Human Papillomavirus in Penile Carcinomas Worldwide.

Alemany L, Cubilla A, Halec G, Kasamatsu E, Quirós B, Masferrer E, Tous S, Lloveras B, Hernández-Suarez G, Lonsdale R, Tinoco L, Alejo M, Alvarado-Cabrero I, Laco J, Guimerà N, Poblet E, Lombardi LE, Bergeron C, Clavero O, Shin HR, Ferrera A, Felix A, Germar J, Mandys V, Clavel C, Tzardi M, Pons LE, Wain V, Cruz E, Molina C, Mota JD, Jach R, Velasco J, Carrilho C, López-Revilla R, Goodman MT, Quint WG, Castellsagué X, Bravo I, Pawlita M, Muñoz N, Bosch FX, de Sanjosé S; HPV VVAP study group.

Eur Urol. 2016 May;69(5):953-61. doi: 10.1016/j.eururo.2015.12.007. Epub 2016 Jan 5.

PMID:
26762611
27.

Training in the prevention of cervical cancer: advantages of e-learning.

Company A, Montserrat M, Bosch FX, de Sanjosé S.

Ecancermedicalscience. 2015 Oct 8;9:580. doi: 10.3332/ecancer.2015.580. eCollection 2015.

28.

Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.

Georgalis L, de Sanjosé S, Esnaola M, Bosch FX, Diaz M.

Eur J Cancer Prev. 2016 Sep;25(5):430-9. doi: 10.1097/CEJ.0000000000000202.

PMID:
26375246
29.

HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry KU, Poljak M, Kjaer SK, Meijer CJ, Garland SM, Salmerón J, Castellsagué X, Bruni L, de Sanjosé S, Cuzick J.

Nat Rev Clin Oncol. 2016 Feb;13(2):119-32. doi: 10.1038/nrclinonc.2015.146. Epub 2015 Sep 1. Review.

PMID:
26323382
30.

Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions.

Ibáñez R, Alejo M, Combalia N, Tarroch X, Autonell J, Codina L, Culubret M, Bosch FX, de Sanjosé S.

Biomed Res Int. 2015;2015:605375. doi: 10.1155/2015/605375. Epub 2015 Jun 9.

31.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

32.

Screening of cervical cancer in Catalonia 2006-2012.

de Sanjosé S, Ibáñez R, Rodríguez-Salés V, Peris M, Roura E, Diaz M, Torné A, Costa D, Canet Y, Falguera G, Alejo M, Espinàs JA, Bosch FX.

Ecancermedicalscience. 2015 Apr 29;9:532. doi: 10.3332/ecancer.2015.532. eCollection 2015.

33.

Disagreement in high-grade/low-grade intraepithelial neoplasia and high-risk/low-risk HPV infection: clinical implications for anal cancer precursor lesions in HIV-positive and HIV-negative MSM.

Pimenoff VN, Félez-Sánchez M, Tous S, Clavero O, Godínez JM, Klaustermeier J, Saunier M, Molijn A, Alemany L, Quint W, Bosch FX, de Sanjosé S, McCloskey J, Bravo IG.

Clin Microbiol Infect. 2015 Jun;21(6):605.e11-9. doi: 10.1016/j.cmi.2015.02.009. Epub 2015 Feb 17.

34.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

35.

HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis.

Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, Bosch FX, de Sanjosé S, Trottier H.

Lancet Oncol. 2014 Nov;15(12):1319-31. doi: 10.1016/S1470-2045(14)70471-1. Epub 2014 Oct 16. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25439690
36.

Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China).

Serrano B, Alemany L, Ruiz PA, Tous S, Lima MA, Bruni L, Jain A, Clifford GM, Qiao YL, Weiss T, Bosch FX, de Sanjosé S.

Cancer Epidemiol. 2014 Dec;38(6):748-56. doi: 10.1016/j.canep.2014.09.003. Epub 2014 Oct 8.

37.

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.

Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008. doi: 10.1158/1055-9965.EPI-14-0410.

38.

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples.

Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, Joura EA, Maldonado P, Klaustermeier J, Salmerón J, Bergeron C, Petry KU, Guimerà N, Clavero O, Murillo R, Clavel C, Wain V, Geraets DT, Jach R, Cross P, Carrilho C, Molina C, Shin HR, Mandys V, Nowakowski AM, Vidal A, Lombardi L, Kitchener H, Sica AR, Magaña-León C, Pawlita M, Quint W, Bravo IG, Muñoz N, de Sanjosé S, Bosch FX; HPV VVAP study group.

Eur J Cancer. 2014 Nov;50(16):2846-54. doi: 10.1016/j.ejca.2014.07.018. Epub 2014 Aug 21.

PMID:
25155250
39.

Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina.

Iljazović E, Mena M, Tous S, Alemany L, Omeragić F, Sadiković A, Clavero O, Vergara M, Bosch FX, de Sanjosé S.

Cancer Epidemiol. 2014 Oct;38(5):504-10. doi: 10.1016/j.canep.2014.06.004. Epub 2014 Aug 11.

PMID:
25130915
40.

Protecting the underscreened women in developed countries: the value of HPV test.

Ibáñez R, Autonell J, Sardà M, Crespo N, Pique P, Pascual A, Martí C, Fibla M, Gutiérrez C, Lloveras B, Moreno-Crespi J, Torrent A, Baixeras N, Alejo M, Bosch FX, de Sanjosé S.

BMC Cancer. 2014 Aug 8;14:574. doi: 10.1186/1471-2407-14-574.

41.

Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer.

Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M; Retrospective International Survey and HPV Time Trends Study Group; Retrospective International Survey and HPV Time Trends Study Group.

J Pathol. 2014 Dec;234(4):441-51. doi: 10.1002/path.4405. Epub 2014 Sep 12.

PMID:
25043390
42.

Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.

Alemany L, Saunier M, Alvarado-Cabrero I, Quirós B, Salmeron J, Shin HR, Pirog EC, Guimerà N, Hernandez-Suarez G, Felix A, Clavero O, Lloveras B, Kasamatsu E, Goodman MT, Hernandez BY, Laco J, Tinoco L, Geraets DT, Lynch CF, Mandys V, Poljak M, Jach R, Verge J, Clavel C, Ndiaye C, Klaustermeier J, Cubilla A, Castellsagué X, Bravo IG, Pawlita M, Quint WG, Muñoz N, Bosch FX, de Sanjosé S; HPV VVAP Study Group.

Int J Cancer. 2015 Jan 1;136(1):98-107. doi: 10.1002/ijc.28963. Epub 2014 May 30.

43.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L.

J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139. Epub 2014 Mar 8.

44.

Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study.

Albero G, Castellsagué X, Lin HY, Fulp W, Villa LL, Lazcano-Ponce E, Papenfuss M, Abrahamsen M, Salmerón J, Quiterio M, Nyitray AG, Lu B, Bosch FX, Giuliano AR.

BMC Infect Dis. 2014 Feb 10;14:75. doi: 10.1186/1471-2334-14-75.

45.

Coverage of Cervical Cancer Screening in Catalonia for the Period 2008-2011 among Immigrants and Spanish-Born Women.

Rodríguez-Salés V, Roura E, Ibañez R, Peris M, Bosch FX, de Sanjosé S.

Front Oncol. 2013 Dec 20;3:297. doi: 10.3389/fonc.2013.00297. eCollection 2013.

46.

Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.

Alemany L, de Sanjosé S, Tous S, Quint W, Vallejos C, Shin HR, Bravo LE, Alonso P, Lima MA, Guimerà N, Klaustermeier J, Llombart-Bosch A, Kasamatsu E, Tatti SA, Felix A, Molina C, Velasco J, Lloveras B, Clavero O, Lerma E, Laco J, Bravo IG, Guarch R, Pelayo A, Ordi J, Andújar M, Sanchez GI, Castellsagué X, Muñoz N, Bosch FX; RIS HPV TT Study Group.

Int J Cancer. 2014 Jul 1;135(1):88-95. doi: 10.1002/ijc.28636. Epub 2013 Dec 30.

47.

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.

Castellsagué X, Paavonen J, Jaisamrarn U, Wheeler CM, Skinner SR, Lehtinen M, Naud P, Chow SN, Del Rosario-Raymundo MR, Teixeira JC, Palmroth J, de Carvalho NS, Germar MJ, Peters K, Garland SM, Szarewski A, Poppe WA, Romanowski B, Schwarz TF, Tjalma WA, Bosch FX, Bozonnat MC, Struyf F, Dubin G, Rosillon D, Baril L; HPV PATRICIA Study Group.

BMC Infect Dis. 2014 Oct 30;14:551. doi: 10.1186/s12879-014-0551-y.

48.

Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort.

Roura E, Castellsagué X, Pawlita M, Travier N, Waterboer T, Margall N, Bosch FX, de Sanjosé S, Dillner J, Gram IT, Tjønneland A, Munk C, Pala V, Palli D, Khaw KT, Barnabas RV, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Fagherazzi G, Kaaks R, Lukanova A, Steffen A, Trichopoulou A, Trichopoulos D, Klinaki E, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita HB, Peeters PH, Lund E, Weiderpass E, Redondo ML, Sánchez MJ, Tormo MJ, Barricarte A, Larrañaga N, Ekström J, Hortlund M, Lindquist D, Wareham N, Travis RC, Rinaldi S, Tommasino M, Franceschi S, Riboli E.

Int J Cancer. 2014 Jul 15;135(2):453-66. doi: 10.1002/ijc.28666. Epub 2014 Jan 6.

49.

Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort.

Castellsagué X, Pawlita M, Roura E, Margall N, Waterboer T, Bosch FX, de Sanjosé S, Gonzalez CA, Dillner J, Gram IT, Tjønneland A, Munk C, Pala V, Palli D, Khaw KT, Barnabas RV, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Fagherazzi G, Kaaks R, Lukanova A, Steffen A, Trichopoulou A, Trichopoulos D, Klinaki E, Tumino R, Sacerdote C, Mattiello A, Bueno-de-Mesquita HB, Peeters PH, Lund E, Weiderpass E, Quirós JR, Sánchez MJ, Navarro C, Barricarte A, Larrañaga N, Ekström J, Hortlund M, Lindquist D, Wareham N, Travis RC, Rinaldi S, Tommasino M, Franceschi S, Riboli E.

Int J Cancer. 2014 Jul 15;135(2):440-52. doi: 10.1002/ijc.28665. Epub 2014 Jan 6.

50.

The path to eliminate cervical cancer in the world and the challenges of professional education.

Bosch FX; Editors.

Vaccine. 2013 Dec 31;31 Suppl 7:xi-xii. doi: 10.1016/j.vaccine.2013.10.008. No abstract available.

PMID:
24332302

Supplemental Content

Loading ...
Support Center